Page 9 - Scientific Library

Lipodystrophies are disorders characterized by complete or selective loss of adipose tissue from various regions of the body. They might lead to severe metabolic disorders. The development of reliable

Genome editing technology enabled by CRISPR and TALEN has become mainstream. Most cell biology labs are engaged in projects to create custom cell lines with knock-outs and knock-ins, and companies such

Recently I reported about methods to measure:

• Collagen - Sircol for soluble and insoluble collagen assays
• Glycosaminoglycans - How to measure Glycosaminoglycans and Proteoglycans?

Today, I invite you to

Many labs have adopted the CRISPR genome editing technology to make knock-out and knock-in cell lines.

This technology produces first a targeted break in genomic DNA, which can then be exploited to produce

Diabetes is a major health concern. And its research can be a nightmare sometimes. tebu-bio strive to offer a comprehensive range of research tools and services to study Obesity, Diabetes, and Metabolic

Biomarkers specialists are often asked to select an ELISA kit for researchers: with thousands of ELISA references available on the market, the choice can be tricky regarding proteins for which several

Interferons (IFNs) are low molecular weight proteins that belong to the class of glycoproteins known as cytokines. IFNs are part of the non-specific immune system and are an important first line of defense

In previous posts, we have discussed about whether samples should be pooled, how much (and if) they should be diluted, and how biologicals can affect the final results...and the biomarkers that you find.

A recent review by Nadim et al. casts some light on a Cosmetology and Dermatology, where circulating biomarkers, though studied to a certain extent so far, are yet unknown for many skin models. (1) 

CRISPR/Cas9 is relatively simple to implement, as the researcher fully controls the experimental design of the tools, from the sgRNA sequence to the Cas9 protein.

A recent article by E. Langer (E. Langer, “Another In-House Operation Gets Outsourced” (2015) Pharmaceutical Technology 39 (6)) describes the growing